A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents

The outcome of patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agents (HMAs) failure is poor with a median overall survival (OS) of only 4–6 months. Omacetaxine mepesuccinate (OM) is safe and effective in myeloid malignancies but has not been studied in MDS with HMA fa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Hematol
Main Authors: Short, Nicholas J., Jabbour, Elias, Naqvi, Kiran, Patel, Ami, Ning, Jing, Sasaki, Koji, Nogueras-Gonzalez, Graciela M., Bose, Prithviraj, Kornblau, Steven M., Takahashi, Koichi, Andreeff, Michael, Sanchez-Petitto, Gabriela, Estrov, Zeev, Dinardo, Courtney D., Montalban-Bravo, Guillermo, Konopleva, Marina, Alvarado, Yesid, Bhalla, Kapil N., Fiskus, Warren, Khouri, Maria, Islam, Rubiul, Kantarjian, Hagop, Garcia-Manero, Guillermo
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6570401/
https://ncbi.nlm.nih.gov/pubmed/30328139
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25318
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados